Eli Lilly announced a $6.3 billion acquisition of U.K.-based Centessa Pharmaceuticals, a clinical-stage biotech focused on neuroscience. The deal includes up to $1.5 billion in milestone payments tied to Centessa's lead drug candidate cleminorexton for sleep-wake disorders. Despite the large price tag, Lilly's stock reacted positively due to the company's strong financial position, bolstered by the success of weight-loss drugs Zepbound and Mounjaro. The acquisition represents Lilly's strategy of both building and acquiring assets for continued growth.

A major M&A week sees Sysco acquiring Restaurant Depot for $26 billion and McCormick merging with Unilever's food division for $44 billion, while Eli Lilly acquires Centessa Pharmaceuticals for $7.8 billion. The podcast discusses the track record of consumer brand mergers (mostly unsuccessful) and analyzes Whirlpool as a dividend investment amid housing market headwinds.

Major M&A activity dominates the market with McCormick merging with Unilever's Foods business in a $29.1 billion deal, Sysco acquiring Jetro Restaurant Depot for $29 billion, and Eli Lilly acquiring Centessa Pharmaceuticals for $7.8 billion. Meanwhile, QVC faces financial distress and is considering Chapter 11 bankruptcy, while several other companies including IO Biotech and Lipella Pharmaceuticals have filed for bankruptcy.

Eli Lilly commits over $10 billion to two major strategic initiatives: a $2.75 billion expanded partnership with InSilico Medicine to leverage AI for drug discovery, and a $6.3-7.8 billion acquisition of Centessa Pharmaceuticals to enter the sleep-wake disorders market. These moves aim to modernize R&D processes, diversify revenue beyond its GLP-1 franchise, and support the company's premium valuation.

Eli Lilly and Company has agreed to acquire Centessa Pharmaceuticals, which developed an OX2R agonist pipeline for sleep-wake disorders in collaboration with Nxera Pharma. Nxera retains material economic interests including milestone payments, royalties, and an equity stake in Centessa. The acquisition validates Nxera's drug discovery platform and complements Nxera's existing multi-target collaboration with Lilly worth up to $694 million in potential milestones.

Eli Lilly has agreed to acquire Centessa Pharmaceuticals, which is developing an OX2R agonist pipeline for sleep-wake disorders jointly discovered with Nxera. Nxera retains milestone payments, royalties, and an equity interest in Centessa under the transaction. Nxera also maintains a separate collaboration with Lilly on metabolic disease drug discovery.

Eli Lilly agreed to acquire Centessa Pharmaceuticals for approximately $6.3 billion upfront plus up to $1.5 billion in contingent payments. The acquisition expands Lilly's neuroscience portfolio with Centessa's orexin receptor 2 agonist pipeline, including the lead candidate cleminorexton for sleep disorders. The deal is expected to close in Q3 pending shareholder and regulatory approval. Centessa shares surged 45% on the announcement.

While Centessa Pharmaceuticals shows promise with its ORX750 narcolepsy candidate, the article argues that Vertex Pharmaceuticals is a superior investment choice. Vertex has an established profitable business in cystic fibrosis, recent successful launches like Journavx and Casgevy, and a strong late-stage pipeline including zimislecel for Type 1 diabetes. Centessa, as a pre-revenue biotech, carries significantly higher risk despite its promising pipeline.

Commodore Capital significantly reduced its stake in Centessa Pharmaceuticals by selling 1.85 million shares (worth ~$46.86 million) in Q4, cutting its position from over 9% to 1.66% of assets. The sale comes as CNTA stock has surged 53.4% over the past year. The fund's move suggests capital redeployment amid Centessa's strategic shift toward focusing on its orexin franchise under new CEO Mario Accardi, raising questions about concentration risk versus the potential of the company's narrowed pipeline.

Nxera Pharma announced that its research collaboration partner Centessa Pharmaceuticals achieved an early development milestone with ORX489, an orexin receptor 2 agonist for neuropsychiatric disorders. The achievement triggers a $1.8 million milestone payment to Nxera, which will be recognized as revenue in Q1 2026.

Tanager Wealth Management exited its entire position in Centessa Pharmaceuticals (CNTA), selling 598,044 shares for approximately $14.5 million in the fourth quarter. The biotech stock had surged nearly 57% over the past year, significantly outperforming the S&P 500. The fund's exit reflects a strategy to reduce oversized positions after sharp rallies, despite Centessa's improving fundamentals including strong cash reserves and a recent CEO transition.

Centessa Pharmaceuticals presented preclinical data at the 64th ACNP Annual Meeting showing that OX2R activation with their agonist CNT-9982 reduced behavioral despair and enhanced wakefulness in animal models of major depressive disorder. The company plans to expand its OX2R agonist pipeline beyond rare hypersomnias into additional neuropsychiatric indications with high unmet clinical need.